TABLE 2

Antibiotics used in combination with polymyxins in patients receiving NVCT and VCT

Antibiotic used in combination with polymyxinsaNVCT group (n = 203)VCT group (n = 30)
No. (%) of patientsNo. (%) of patients with infection-related mortalityNo. (%) of patientsNo. (%) of patients with infection-related mortality
Carbapenemsb124 (61.1)37 (29.8)20 (66.7)4 (20.0)
Fluoroquinolonesc52 (25.6)16 (30.8)7 (23.3)1 (14.3)
Beta-lactam–beta-lactamase inhibitord51 (25.1)8 (15.7)1 (3.3)0 (0.0)
Aminoglycosidese14 (6.9)4 (28.6)6 (20.0)1 (16.7)
Cephalosporinsf37 (18.3)6 (16.2)0 (0.0)
Aztreonam13 (6.4)2 (15.4)4 (13.3)0 (0.0)
Rifampin28 (13.8)11 (39.3)4 (13.3)1 (25.0)
Tigecycline46 (22.7)12 (26.1)1 (3.3)0 (0.0)
  • a Each patient could receive more than 1 type of polymyxin combination throughout the treatment course.

  • b The carbapenems used included meropenem, ertapenem, doripenem, and imipenem-cilastin.

  • c The fluoroquinolones used included levofloxacin and ciprofloxacin.

  • d The beta-lactam–beta-lactamase inhibitors used included piperacillin-tazobactam, ampicillin-sulbactam, and amoxicillin-clavulanate.

  • e The aminoglycosides used included amikacin and gentamicin.

  • f The cephalosporins used included ceftazidime, ceftriaxone, and cefepime.